Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.

Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, Ferro M.

Eur Urol Oncol. 2018 Oct;1(5):403-410. doi: 10.1016/j.euo.2018.06.006. Epub 2018 Jul 13.

PMID:
31158079
2.
3.
4.

Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.

Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH, Tollefson MK.

Eur Urol. 2014 Dec;66(6):1157-64. doi: 10.1016/j.eururo.2014.02.042. Epub 2014 Feb 26.

PMID:
24630414
5.

Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.

Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, Rubinstein J, Halachmi S.

Urol Oncol. 2015 Feb;33(2):67.e1-7. doi: 10.1016/j.urolonc.2014.06.010. Epub 2014 Jul 21.

PMID:
25060672
7.

Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.

Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, Shariat SF.

Urol Oncol. 2018 Sep;36(9):389-399. doi: 10.1016/j.urolonc.2018.05.014. Epub 2018 Jun 6. Review.

PMID:
29884342
8.

Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.

Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdona S, Verze P, La Rocca R, Borghesi M, Schiavina R, Brunocilla E, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Serretta V, Russo GI, Morgia G, Terracciano D, Musi G, de Cobelli O, Mirone V, Shariat SF.

Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6.

PMID:
30077463
9.

Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.

Song A, Eo W, Lee S.

World J Gastroenterol. 2015 Nov 21;21(43):12410-20. doi: 10.3748/wjg.v21.i43.12410.

10.

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J.

Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.

PMID:
26210894
11.

Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.

Chen Y, Wang W, Zhang X, Yu X, Xi K, Wen Y, Wang G, Feng X, Zhang L.

Cancer Manag Res. 2018 Nov 8;10:5411-5422. doi: 10.2147/CMAR.S177320. eCollection 2018.

12.

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.

JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657.

13.

Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study.

Favilla V, Castelli T, Urzì D, Reale G, Privitera S, Salici A, Russo GI, Cimino S, Morgia G.

Int Braz J Urol. 2016 Jul-Aug;42(4):685-93. doi: 10.1590/S1677-5538.IBJU.2015.0243.

14.

Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.

Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, Mathieu R, Rouprêt M, Briganti A, Karakiewicz PI, Klatte T.

Urol Oncol. 2016 Nov;34(11):483.e17-483.e24. doi: 10.1016/j.urolonc.2016.05.013. Epub 2016 Sep 16.

PMID:
27646875
15.

Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer.

Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S.

BMC Urol. 2018 Oct 22;18(1):90. doi: 10.1186/s12894-018-0404-x.

16.

Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study.

Zhang Y, Xie L, Chen T, Xie W, Wu Z, Xu H, Xing C, Sha N, Shen Z, Qie Y, Liu X, Hu H, Wu C.

Onco Targets Ther. 2016 Jan 28;9:605-11. doi: 10.2147/OTT.S99866. eCollection 2016.

17.

Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.

Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, Beckers GMA, van Moorselaar RJA.

Eur Urol. 2018 Feb;73(2):226-232. doi: 10.1016/j.eururo.2017.06.038. Epub 2017 Jul 10.

PMID:
28705539
18.

Intravesical electromotive drug administration for non-muscle invasive bladder cancer.

Jung JH, Gudeloglu A, Kiziloz H, Kuntz GM, Miller A, Konety BR, Dahm P.

Cochrane Database Syst Rev. 2017 Sep 12;9:CD011864. doi: 10.1002/14651858.CD011864.pub2. Review.

19.

Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy.

Kawahara T, Furuya K, Nakamura M, Sakamaki K, Osaka K, Ito H, Ito Y, Izumi K, Ohtake S, Miyoshi Y, Makiyama K, Nakaigawa N, Yamanaka T, Miyamoto H, Yao M, Uemura H.

BMC Cancer. 2016 Mar 5;16:185. doi: 10.1186/s12885-016-2219-z.

20.

Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.

Zhang GM, Zhu Y, Luo L, Wan FN, Zhu YP, Sun LJ, Ye DW.

Tumour Biol. 2015 Nov;36(11):8537-43. doi: 10.1007/s13277-015-3613-x. Epub 2015 Jun 2.

PMID:
26032095

Supplemental Content

Support Center